Hike in UK fees for drug/device combination products
This article was originally published in Clinica
Executive Summary
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is increasing its fees for marketing authorisations for drug/device combination products by just over 10%, with affect from April 1.